Key result
Combined hypercoagulability and impaired fibrinolysis significantly increased the risk of MACE over 4 years compared to normal parameters (adjusted HR 1.863; 95% CI 1.191-2.913; P=0.006).
Why the study?
Although plaque rupture is common, catastrophic clinical events are not, leading researchers to hypothesize that hypercoagulability and impaired fibrinolysis influence coronary thrombosis risk and long-term prognosis in CAD.
Do hypercoagulability and impaired fibrinolysis increase the risk of MACE in CAD patients undergoing PCI?
Population
2,705 CAD patients undergoing PCI
Comparison
Combined MA ≥68 mm and LY30 <0.2% vs MA <68 mm and LY30 ≥0.2%
Design
Cohort study
Follow-up
4 years
Authors
Loading...
High MA with low LY30 flags elevated post-PCI MACE risk; extends thromboelastography for CAD risk stratification.
Cohort (n=2,705)
Do hypercoagulability and impaired fibrinolysis increase the risk of MACE in CAD patients undergoing PCI?
Hazard Ratio: 1.863 (95% CI 1.191–2.913)
p-value: p=0.006
Hypercoagulability and impaired fibrinolysis, as measured by thromboelastography, are associated with an increased risk of AMI presentation and long-term MACE following PCI.
Kim et al. (2021) conducted a cohort in Coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) (n=2,705). Combined hypercoagulability (MA≥68 mm) and impaired fibrinolysis (LY30<0.2%) vs. MA<68 mm and LY30≥0.2% was evaluated on Major adverse cardiovascular events (MACEs) (composite of cardiovascular death, myocardial infarction, or stroke) (adjusted HR 1.863, 95% CI 1.191-2.913, p=0.006). Combined hypercoagulability and impaired fibrinolysis significantly increased the risk of MACE over 4 years compared to normal parameters (adjusted HR 1.863; 95% CI 1.191-2.913; P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: